Arbutus Biopharma Management
Management criteria checks 3/4
Arbutus Biopharma's CEO is Mike McElhaugh, appointed in Nov 2022, has a tenure of 1.42 years. total yearly compensation is $1.62M, comprised of 29.8% salary and 70.2% bonuses, including company stock and options. directly owns 0.74% of the company’s shares, worth $3.60M. The average tenure of the management team and the board of directors is 2.6 years and 5.5 years respectively.
Key information
Mike McElhaugh
Chief executive officer
US$1.6m
Total compensation
| CEO salary percentage | 29.8% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.7% |
| Management average tenure | 2.6yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Moderna Investors Should Beware Patent-Dispute Fallout
Apr 23Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
Apr 10Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
Feb 10
Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 03Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week
Nov 09Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio
Oct 24We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow
Apr 26Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher
Nov 11We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Oct 28Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'
Sep 12Arbutus stock rises on US patent linked to hepatitis B therapy AB-729
Aug 30Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts
Aug 06Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial
Jul 20Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
Jun 29We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
Jun 15Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic
May 11Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues
Mar 08Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
Mar 07Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?
Dec 17Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
Dec 14Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Nov 20Arbutus Biopharma: A First Assessment
Sep 15We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
Sep 11Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
Jun 29Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans
May 21Arbutus Bio slips 4% as Q1 revenue trails consensus
May 05What You Need To Know About Arbutus Biopharma Corporation's (NASDAQ:ABUS) Investor Composition
Mar 12We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth
Feb 02Arbutus Biopharma's (NASDAQ:ABUS) Stock Price Has Reduced 29% In The Past Three Years
Jan 07Arbutus Biopharma (ABUS) Investor Presentation - Slideshow
Dec 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$483k | -US$73m |
| Sep 30 2023 | n/a | n/a | -US$75m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$70m |
| Dec 31 2022 | US$1m | US$449k | -US$69m |
| Sep 30 2022 | n/a | n/a | -US$69m |
| Jun 30 2022 | n/a | n/a | -US$76m |
| Mar 31 2022 | n/a | n/a | -US$85m |
| Dec 31 2021 | n/a | n/a | -US$88m |
| Sep 30 2021 | n/a | n/a | -US$87m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$79m |
| Dec 31 2020 | US$1m | US$415k | -US$76m |
Compensation vs Market: Mike's total compensation ($USD1.62M) is below average for companies of similar size in the US market ($USD2.37M).
Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.
CEO
Mike McElhaugh (48 yo)
1.4yrs
Tenure
US$1,620,485
Compensation
Mr. Michael J. McElhaugh, also known as Mike, co-founded Arbutus Biopharma Inc. in 2012 and serves as its Interim President and Chief Executive Officer and Director since January 1, 2024. Mr. McElhaugh had...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 1.4yrs | US$1.62m | 0.74% $ 3.6m | |
| Chief Scientific Officer | 9.3yrs | US$1.61m | 0.83% $ 4.0m | |
| CFO & Chief Accounting Officer | 5.8yrs | US$1.46m | 0.0093% $ 45.5k | |
| Vice President of Investor Relations | 2.6yrs | no data | no data | |
| General Counsel | less than a year | no data | no data | |
| Vice President of Human Resources | no data | no data | no data | |
| Chief Medical Officer | less than a year | no data | 0.0029% $ 14.4k | |
| Corporate Secretary | 13.9yrs | no data | no data |
2.6yrs
Average Tenure
59yo
Average Age
Experienced Management: ABUS's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | less than a year | US$1.62m | 0.74% $ 3.6m | |
| Independent Non-Executive Director | 9.3yrs | US$136.42k | 0.00056% $ 2.7k | |
| Independent Director | 7.1yrs | US$161.74k | 0% $ 0 | |
| Independent Non-Executive Director | 9.1yrs | US$156.74k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.5yrs | US$176.74k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 5.5yrs | no data | 0% $ 0 | |
| Independent Chairman of the Board of Directors | 5.4yrs | US$187.99k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
5.5yrs
Average Tenure
56.5yo
Average Age
Experienced Board: ABUS's board of directors are considered experienced (5.5 years average tenure).